CALCA and medullary thyroid gland carcinoma: While calcitonin remains the cornerstone of MTC diagnosis, emerging biomarkers such as procalcitonin and advanced genetic/molecular profiling may further refine risk assessment and management strategies, ultimately improving patient outcomes.